Sabrina Browning, MD
Assistant Professor of Medicine (Hematology)
Research & Publications
Biography
News
Research Summary
Dr. Browning's research interests include the study of new treatments for multiple myeloma and AL amyloidosis as well as the effect of therapy on patients' quality of life. She is also interested in exploring potential inherited risk factors for the development of these diseases. She will be pursuing studies to better understand how to manage classic hematology problems, including clotting and bleeding, which may occur in patients with multiple myeloma or AL amyloidosis. She has also worked with the Yale Convalescent Plasma Therapy in COVID-19 group to investigate the role of transfusing plasma collected from donors who have recovered from COVID-19 to those currently sick with the disease in an attempt to improve their breathing status and other outcomes.
Coauthors
Research Interests
Quality of Life; Therapeutics; Exome Sequencing
Selected Publications
- Evaluation of Metabolic Profile in Monoclonal Gammopathy of Undetermined Significance and Asymptomatic Multiple MyelomaBrowning S, Li A, Parker T, Bar N, Anderson T, Stevens E, Liu Y, Matthews M, VanOudenhove J, Cardone R, Sun Q, Hale R, Halene S, Kibbey R, Neparidze N. Evaluation of Metabolic Profile in Monoclonal Gammopathy of Undetermined Significance and Asymptomatic Multiple Myeloma. Blood 2023, 142: 4774. DOI: 10.1182/blood-2023-186401.
- Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple MyelomaBrowning S, Liu Y, Parker T, Bar N, Anderson T, Dhodapkar M, Seropian S, Halene S, Xu M, Syam R, Gorshein E, DiAdamo A, Talsania A, Kidwai W, Witt D, Chang V, Montanari F, Lischuk A, Wei W, Haims A, Neparidze N. Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma. Blood 2022, 140: 7308-7310. DOI: 10.1182/blood-2022-166325.
- Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction TherapyLiu Y, Browning S, VanOudenhove J, Biancon G, Bar N, Parker T, Anderson T, Dhodapkar M, Seropian S, Halene S, Xu M, Gorshein E, Talsania A, Kidwai W, Witt D, Chang V, Montanari F, Lischuk A, Haims A, Wei W, Neparidze N. Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy. Blood 2022, 140: 7086-7087. DOI: 10.1182/blood-2022-168109.
- Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale ExperienceLiu Y, Kywe B, Crawford L, Lora F, Bar N, Browning S, Gorshein E, Parker T, Neparidze N. Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience. Blood 2021, 138: 1635. DOI: 10.1182/blood-2021-146619.
- Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer CenterDosani T, Poteraj A, Parker T, Bar N, Browning S, Gorshein E, Anderson T, Insogna K, Neparidze N. Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center. Blood 2021, 138: 4756. DOI: 10.1182/blood-2021-147466.
- Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19Briggs N, Gormally MV, Li F, Browning SL, Treggiari MM, Morrison A, Laurent-Rolle M, Deng Y, Hendrickson JE, Tormey CA, Desruisseaux MS. Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19. PLOS ONE 2021, 16: e0254453. PMID: 34320004, PMCID: PMC8318280, DOI: 10.1371/journal.pone.0254453.
- Forming the Hematology-Oncology Collaborative Videoconferencing (CO-VID) Learning Initiative: Experiential Lessons Learned From a Novel Trainee-Led Multidisciplinary Virtual Learning PlatformMartin RL, Grant MJ, Kimani S, Midha S, May J, Patell R, Collier E, Furfaro D, Bodine C, Reap L, Shah N, DeLaune J, Brusca S, Olazagasti C, Goyal S, Rubinstein S, Hakim N, Qin S, Browning SL, Sena L, Gilbert J, Davidson M, Lovly CM, Seetharamu N, Rangachari D, Murphy M, Chatwal M, Paschal R, Henry E, Collichio F, Green JR. Forming the Hematology-Oncology Collaborative Videoconferencing (CO-VID) Learning Initiative: Experiential Lessons Learned From a Novel Trainee-Led Multidisciplinary Virtual Learning Platform. JCO Oncology Practice 2021, 18: e36-e46. PMID: 34242082, PMCID: PMC8758064, DOI: 10.1200/op.20.00960.
- Advanced Imaging and Targeted Myeloma Lesion Biopsies to Enhance Global Response Assessment and Evaluate Spatial Heterogeneity in Multiple MyelomaBrowning S, Parker T, Bar N, Anderson T, Dhodapkar M, Seropian S, Lee A, Prebet T, Halene S, Xu M, Gorshein E, Talsania A, Kidwai W, Witt D, Chang V, Lischuk A, Wei W, Haims A, Neparidze N. Advanced Imaging and Targeted Myeloma Lesion Biopsies to Enhance Global Response Assessment and Evaluate Spatial Heterogeneity in Multiple Myeloma. Blood 2020, 136: 20-22. DOI: 10.1182/blood-2020-136478.
- Use of Convalescent Plasma Therapy in Severe Coronavirus Disease 2019: The Yale-New Haven Health System ExperienceBrowning S, Gormally M, Briggs N, Li M, Zakko A, Laurent-Rolle M, Ladines-Lim J, Morrison A, Kandel P, Khan M, McLeod G, Buller G, Owusu K, Treggiari M, Hendrickson J, Tormey C, Desruisseaux M. Use of Convalescent Plasma Therapy in Severe Coronavirus Disease 2019: The Yale-New Haven Health System Experience. Blood 2020, 136: 39-40. PMCID: PMC8330251, DOI: 10.1182/blood-2020-137352.
- Spontaneous recovery in a patient with acquired thrombotic thrombocytopenic purpura (TTP): observation of a ‘subclinical’ TTP stateBrowning S, Bahar B, Lee AI, Gorshein E. Spontaneous recovery in a patient with acquired thrombotic thrombocytopenic purpura (TTP): observation of a ‘subclinical’ TTP state. Hematology 2020, 25: 473-477. PMID: 33269995, DOI: 10.1080/16078454.2020.1848973.
- Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer CenterBrowning S, Parker T, Bar N, Seropian S, Lee A, Anderson T, Neparidze N. Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center. Blood 2019, 134: 5569. DOI: 10.1182/blood-2019-130134.
- Hereditary Renal Amyloidosis Associated With a Novel Apolipoprotein A-II VariantProkaeva T, Akar H, Spencer B, Havasi A, Cui H, O’Hara C, Gursky O, Leszyk J, Steffen M, Browning S, Rosenberg A, Connors LH. Hereditary Renal Amyloidosis Associated With a Novel Apolipoprotein A-II Variant. Kidney International Reports 2017, 2: 1223-1232. PMID: 29270531, PMCID: PMC5733886, DOI: 10.1016/j.ekir.2017.07.009.
- Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantationBrowning S, Quillen K, Sloan JM, Doros G, Sarosiek S, Sanchorawala V. Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation. Blood 2017, 130: 1383-1386. PMID: 28698204, DOI: 10.1182/blood-2017-06-788729.
- Current Management of Sickle Cell Disease in PregnancyAndemariam B, Browning SL. Current Management of Sickle Cell Disease in Pregnancy. Clinics In Laboratory Medicine 2013, 33: 293-310. PMID: 23702119, DOI: 10.1016/j.cll.2013.03.023.